Phase 2Completed
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy (ROSE2)
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study
- Sponsor
- NewAmsterdam Pharma (Industry)
- Enrollment
- 119 enrolled
- Conditions
- Dyslipidemias; High Cholesterol; Hypercholesterolemia
- Interventions
- Obicetrapib; Ezetimibe 10mg; Obicetrapib placebo; Ezetimibe placebo
- Ages
- adults, older adults
- Registry
- NCT05266586
Full record on ClinicalTrials.gov
From the registry
This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.
Primary outcomes
- Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]
- Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]
- LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]
- Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]
History
Results first posted
Last registry update
Study completion
Primary completion
Started
Registered